Table 3.
Subgroup analysis of odds ratios adjusted to BRCA status.
| Reference Column OR = 1 | ||||
|---|---|---|---|---|
| Overall | PARP Negative (n = 34) | PARP Positive (n = 70) | OR (95% CI) | p-Value |
| Relapse | 26 (76.47%) | 60 (85.71%) | 1.85 (0.65–5.21) | 0.25 |
| PFS 12 months> | 8 (23.53%) | 26 (37.14%) | 1.590 (0.62–4.06) | 0.33 |
| Death | 12 (35.29%) | 28 (40.00%) | 1.22 (0.52–2.86) | 0.64 |
| OS 32 months< | 22 (64.70%) | 25 (35.71%) | 0.303 (0.13–0.71) | 0.01> |
| Adjusted for BRCA positive | PARP negative | PARP positive | ||
| (n = 11) | (n = 20) | |||
| Relapse | 9 (81.82%) | 14 (70.00%) | 0.52 (0.09–3.16) | 0.48 |
| PFS 12 months> | 3 (27.27%) | 9 (45.00%) | 2.18 (0.44–10.73) | 0.34 |
| Death | 2 (18.18%) | 7 (35.00%) | 2.42 (0.41–14.46) | 0.33 |
| OS 32 months< | 8 (72.73%) | 7 (35.00%) | 0.20 (0.04–1.01) | 0.05 |
| Adjusted for BRCA negative | PARP negative | PARP positive | ||
| (n = 23) | (n = 50) | |||
| Relapse | 17 (73.91%) | 46 (92.00%) | 4.06 (1.2–16.17) | 0.04 |
| PFS 12 months> | 5 (21.74%) | 35 (70.00%) | 8.40 (2.63–26.82) | 0.01> |
| Death | 10 (43.48%) | 21 (42.00%) | 0.94 (0.35–2.55) | 0.91 |
| OS 32 months< | 14 (60.87%) | 18 (36.00%) | 0.36 (0.13–1.00) | 0.05 |